[ET Net News Agency, 24 December 2021] Shanghai Junshi Biosciences Co., Ltd. (01877)
said the company has received the Acceptance Notice issued by the National Medical
Products Administration. The investigational new drug application for the JS001sc
injection (project code: JS001sc) has been accepted. The application matter is Clinical
Trial of Domestic Production Registration of Pharmaceutical Product.
JS001sc injection is a subcutaneous injection formulation developed by the company on
the basis of the marketed product Toripalimab Injection (trade name: TUOYI, product code:
JS001). (RC)